Drugs for Sclerosing Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 75)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bezafibrate |
Approved, Investigational |
Phase 3 |
|
41859-67-0 |
39042 |
Synonyms:
2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionate
2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
Azufibrat
Azupharma brand OF bezafibrate
Bayer brand OF bezafibrate
Befibrat
Befizal
Béfizal
Berlin chemie brand OF bezafibrate
Berlin-chemie brand OF bezafibrate
Betapharm brand OF bezafibrate
Beza lande
Beza puren
Bezabeta
Bezacur
Bezafibrat
Bezafibrat PB
BEZAFIBRATE
Bezafibrate azupharma brand
Bezafibrate bayer brand
Bezafibrate berlin-chemie brand
Bezafibrate betapharm brand
Bezafibrate cryopharma brand
Bezafibrate elfar brand
Bezafibrate hennig brand
Bezafibrate hexal brand
Bezafibrate isis brand
Bezafibrate lakeside brand
Bezafibrate merckle brand
Bezafibrate roche brand
Bezafibrate synthelabo brand
Bezafibrate tad brand
Bezafibrate teva brand
Bezafibrato
Bezafibratum
Bezafibric acid
Bezafisal
BEZAGEN XL
|
Beza-lande
BezaLande
Bezalip
Bezalip®
BEZALIP-MONO
Bezamerck
Beza-puren
BezaPuren
Bezatol SR
BEZATOL SR (TN)
BM 15.075
BM-15.075
BM-15075
Boehringer mannheim brand OF bezafibrate
Cedur
Cryopharma brand OF bezafibrate
Difaterol
Durabezur
Elfar brand OF bezafibrate
Eulitop
FIBRAZATE XL
Hennig brand OF bezafibrate
Hexal brand OF bezafibrate
Isis brand OF bezafibrate
Lakeside brand OF bezafibrate
LIPAROL XL
Lipox
Merckle brand OF bezafibrate
PB, Bezafibrat
Reducterol
Regadrin b
Roche brand OF bezafibrate
Sklerofibrat
Solibay
Synthelabo brand OF bezafibrate
TAD brand OF bezafibrate
Teva brand OF bezafibrate
ZIMBACOL XL
|
|
2 |
|
Simvastatin |
Approved |
Phase 3 |
|
79902-63-9 |
54454 |
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8AR)-8-{2-[(2R,4R)-4-HYDROXY-6-OXOOXAN-2-YL]ETHYL}-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2,2-DIMETHYLBUTANOATE
2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
C10AA01
Cholestat
Coledis
Colemin
Corolin
Denan
Eucor
FLOLIPID
Kolestevan
Labistatin
LACERSA
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
Medipo
MK-0733
MK-733
MK-733|Zocor®
Modutrol
Nivelipol
Nor-vastina
Pantok
Pepstatin
RANZOLONT
|
Rechol
Rendapid
Simcor
Simovil
SIMVADOR
SIMVASTATIN
Simvastatin [Usan:Ban:Inn]
SIMVASTATIN HYDROXY ACID
Simvastatin lactone
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
SIV691
Sivastin
Statin
Synvinolin
Valemia
Vasotenal
Velostatin
Vytorin
Zocor
ZOCOR HEART-PRO
Zocord
|
|
3 |
|
Ursodeoxycholic acid |
Approved, Investigational |
Phase 2, Phase 3 |
|
128-13-2 |
31401 |
Synonyms:
(3a,5b,7b)-3,7-Dihydroxycholan-24-Oate
(3a,5b,7b)-3,7-Dihydroxy-cholan-24-Oate
(3a,5b,7b)-3,7-Dihydroxycholan-24-Oic acid
(3a,5b,7b)-3,7-Dihydroxy-cholan-24-Oic acid
(3alpha,5beta,7beta)-3,7-Dihydroxycholan-24-Oate
(3alpha,5beta,7beta)-3,7-Dihydroxycholan-24-Oic acid
(3Α,5β,7β)-3,7-dihydroxycholan-24-Oate
(3Α,5β,7β)-3,7-dihydroxycholan-24-Oic acid
(4R)-4-[(1S,2S,5R,7S,9S,10R,11S,14R,15R)-5,9-DIHYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0?,?.0??,??]HEPTADECAN-14-YL]PENTANOIC ACID
3 alpha,7 beta Dihydroxy 5 beta cholan 24 Oic acid
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-Oic acid
3,7-Dihydroxycholan-24-Oic acid
3a,7b-Dihydroxy-5b-cholan-24-Oate
3a,7b-Dihydroxy-5b-cholan-24-Oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-Oate
3alpha,7beta-Dihydroxy-5beta-cholan-24-Oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3Α,7β-dihydroxy-5β-cholan-24-Oate
3Α,7β-dihydroxy-5β-cholan-24-Oic acid
ACG240
Acid, deoxyursocholic
Acid, ursacholic
Acid, ursodeoxycholic
Acide ursodesoxycholique
Acido ursodeossicolico
Acido ursodeoxicolico
Acidum ursodeoxycholicum
Actigall
Antigall
Antigen brand OF ursodeoxycholic acid
Aventis brand OF ursodeoxycholic acid
Axcan brand OF ursodeoxycholic acid
Cholit-ursan
Cholofalk
CHOLURSO
CP Brand OF ursodeoxycholic acid
Delursan
Deoxyursocholic acid
|
Destolit
Estedi brand OF ursodeoxycholic acid
Falk brand OF ursodeoxycholic acid
Farmasa brand OF ursodeoxycholic acid
Galen brand OF ursodeoxycholic acid
Heumann brand OF ursodeoxycholic acid
Niddapharm brand OF ursodeoxycholic acid
Norgine brand OF ursodeoxycholic acid
NSC-683769
Orphan brand OF ursodeoxycholic acid
Provalis brand OF ursodeoxycholic acid
Sanofi synthelabo brand OF ursodeoxycholic acid
Sodium ursodeoxycholate
Tramedico brand OF ursodeoxycholic acid
UDCA
Urdox
Urosdesoxycholate
Urosdesoxycholic acid
Ursacholic acid
Urso
URSO 250
URSO FORTE
Urso heumann
Ursobilane
Ursochol
Ursodeoxycholate
Ursodeoxycholate, sodium
URSODEOXYCHOLIC ACID
Ursodeoxycholicacid
URSODESOXYCHOLIC ACID
Ursodexycholate
Ursodexycholic acid
Ursodiol
Ursofalk
Ursogal
Ursolite
Ursolvan
Vita brand OF ursodeoxycholic acid
Zambon brand OF ursodeoxycholic acid
|
|
4 |
|
Clofibric Acid |
|
Phase 3 |
|
882-09-7 |
2797 |
Synonyms:
2-(4-Chlorophenoxy)-2-methylpropionate
2-(4-Chlorophenoxy)-2-methylpropionic acid
2-(p-Chlorophenoxy)-2-methylpropionate
2-(p-Chlorophenoxy)-2-methylpropionic acid
2-(p-Chlorophenoxy)isobutyrate
2-(p-Chlorophenoxy)isobutyric acid
4-CPIB
a-(4-Chlorophenoxy)-a-methylpropionate
a-(4-Chlorophenoxy)-a-methylpropionic acid
a-(p-Chlorophenoxy)isobutyrate
a-(p-Chlorophenoxy)isobutyric acid
Acide (p-chlorophenoxy)-2 methyl-2 propionique
Acide clofibrique
Acido clofibrico
Acidum clofibricum
alpha-(4-Chlorophenoxy)-alpha-methylpropionate
alpha-(4-Chlorophenoxy)-alpha-methylpropionic acid
alpha-(p-Chlorophenoxy)isobutyrate
alpha-(p-Chlorophenoxy)isobutyric acid
Chlorfibrinate
|
Chlorfibrinic acid
Chlorofibrinate
Chlorofibrinic acid
Chlorophibrinate
Chlorophibrinic acid
Clofibrate
Clofibrate free acid
CLOFIBRIC ACID
Clofibric acid free acid
Clofibrinic acid
Clofibrinsaeure
CPIB
p-Chlorophenoxyisobutyrate
p-Chlorophenoxyisobutyric acid
PCIB
PCPIB
Α-(4-chlorophenoxy)-α-methylpropionate
Α-(4-chlorophenoxy)-α-methylpropionic acid
Α-(p-chlorophenoxy)isobutyrate
Α-(p-chlorophenoxy)isobutyric acid
|
|
5 |
|
Anticholesteremic Agents |
|
Phase 3 |
|
|
|
6 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 3 |
|
|
|
7 |
|
Mitomycin |
Approved |
Phase 2 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
8 |
|
Curcumin |
Approved, Investigational |
Phase 1, Phase 2 |
|
458-37-7, 84765-67-3 |
969516 |
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
14a-Methyl-9,19-cyclo-5a,9b-cholestane-3b,6a-diol
C.I. 75300
C.I. natural yellow 3
CI natural yellow 3
CI-75300
Cucurmin
Curcuma
CURCUMIN
Curcumin I
Diferaloylmethane
Diferuloylmethane
e 100
E100
E-100
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
|
Hydrastis
INS NO. 100(I)
INS-100(I)
Kacha haldi
Merita earth
Natural yellow 3
NSC-32982
NSC-687842
Orange root
Safran d'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yellow, turmeric
Yo-kin
|
|
9 |
|
Cladribine |
Approved, Investigational |
Phase 2 |
|
4291-63-8 |
20279 |
Synonyms:
(2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2-CdA
2-Chloro-2'-deoxyadenosine
2-Chloro-2'-deoxy-b-adenosine
2-Chloro-2'-deoxy-beta-adenosine
2-Chloro-2'-deoxy-β-adenosine
2-Chloro-6-amino-9-(2-deoxy-b-D-erythro-pentofuranosyl)purine
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-Chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine
2-Chlorodeoxyadenosine
2-Chloro-deoxyadenosine
2ClAdo
2'-Deoxy-2-chloroadenosine
Chlorodeoxyadenosine
|
CLADARIBINE
Cladribina
CLADRIBINE
Cladribinum
CldAdo
LEUSTAT
Leustatin
LITAK
Mavenclad
Mylinax
NSC-05014
NSC-105014
NSC-105014-F
RWJ-26251
|
|
10 |
|
Aldesleukin |
Approved |
Phase 2 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
11 |
|
Sulfasalazine |
Approved |
Phase 2 |
|
599-79-1 |
5353980 5339 5359476 |
Synonyms:
2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoate
2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid
2-Hydroxy-5-((4-((2-pyridinylamino)sulphonyl)phenyl)azo)benzoate
2-Hydroxy-5-((4-((2-pyridinylamino)sulphonyl)phenyl)azo)benzoic acid
2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoate
2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid
2-Hydroxy-5-[4-(pyridin-2-ylsulphamoyl)-phenylazo]-benzoate
2-Hydroxy-5-[4-(pyridin-2-ylsulphamoyl)-phenylazo]-benzoic acid
4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene
4-(Pyridyl-2-amidosulphonyl)-3'-carboxy-4'-hydroxyazobenzene
5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylate
5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid
5-((p-(2-Pyridylsulphamoyl)phenyl)azo)salicylate
5-((p-(2-Pyridylsulphamoyl)phenyl)azo)salicylic acid
5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoate
5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid
5-(4-(2-Pyridylsulphamoyl)phenylazo)-2-hydroxybenzoate
5-(4-(2-Pyridylsulphamoyl)phenylazo)-2-hydroxybenzoic acid
5-(p-(2-Pyridylsulfamyl)phenylazo)salicylate
5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid
5-(p-(2-Pyridylsulphamyl)phenylazo)salicylate
5-(p-(2-Pyridylsulphamyl)phenylazo)salicylic acid
Accucol
Alti-Sulfasalazine
Asulfidine
Azlufidine EN-Tabs
AZOPYRIN
Azopyrine
Azulfidine
AZULFIDINE EN
AZULFIDINE EN-TABS
Azulfidine®|Salazopyridin®|Salazopyrin®|SAS-500
Benzosulfa
COLIZINE
Colo-Pleon
NSC-203730
|
NSC-667219
PMS-Sulfasalazine
Pms-Sulfasalazine E.C.
Reupirin
Rorasul
S.A.S.
S.A.S. Enteric-500
S.A.S.-500
Salazopiridazin
SALAZOPYRIDIN
SALAZOPYRIN
SALAZOPYRIN E.C.
Salazopyrin EN-Tabs
SALAZOPYRIN-EN
Salazosulfapiridina
Salazosulfapyridin
Salazosulfapyridine
Salazosulfapyridinum
Salazosulphapiridina
Salazosulphapyridine
Salazosulphapyridinum
Salicylazosulfapyridine
Salicylazosulphapyridine
Salisulf
SAS-500
Sulcolon
Sulfasalazin
Sulfasalazina
SULFASALAZINE
Sulfasalazinum
Sulphasalazina
Sulphasalazine
Sulphasalazinum
UCINE
W-T Sasp Oral
|
|
12 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
13 |
|
Fenofibrate |
Approved |
Phase 1, Phase 2 |
|
49562-28-9 |
3339 |
Synonyms:
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoate 1-methylethyl ester
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
Abbott brand OF procetofen
ABT-335
ABT-335|Lipantil®|Supralip®|Tricor®
AbZ brand OF procetofen
Aliud brand OF procetofen
Ankebin
Antara
Antara micronized procetofen
Anto brand OF procetofen
Apo feno micro
Apo fenofibrate
Apo-fenofibrate
Apo-feno-micro
Apotex brand OF procetofen
AZU, fenofibrat
Azupharma brand OF procetofen
Betapharm brand OF procetofen
Bouchara brand OF procetofen
CiL
Controlip
CT Arzneimittel brand OF procetofen
CT-Arzneimittel brand OF procetofen
Debat, fénofibrate
Durafenat
Elasterate
Elasterin
Fenobeta
Fenobrate
Fenofanton
Fenofibrat abz
Fenofibrat al
Fenofibrat azu
Fenofibrat FPH
Fenofibrat heumann
Fenofibrat hexal
Fenofibrat ratiopharm
Fenofibrat stada
Fenofibrat von CT
FENOFIBRATE
Fénofibrate debat
Fénofibrate MSD
FENOFIBRATO
Fenofibrato [INN-Spanish]
Fenofibrat-ratiopharm
FENOFIBRATUM
Fenofibratum [INN-Latin]
Fenofibric acid
FENOGAL
FENOGLIDE
Fenotard
Finofibrate
Finofibric acid
FNF
Fournier brand OF procetofen
gate Brand OF procetofen
Gen fenofibrate
Gen-fenofibrate
Genpharm brand OF procetofen
GNR Pharma brand OF procetofen
GNR-Pharma brand OF procetofen
Heumann brand OF procetofen
Heumann, fenofibrat
Hexal brand OF procetofen
Hexal, fenofibrat
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionic acid
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
|
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionic acid
Knoll brand OF procetofen
Lichtenstein brand OF procetofen
Lipanthyl
Lipantil
LIPANTIL (TN)
LIPANTIL MICRO 200
LIPANTIL MICRO 267
LIPANTIL MICRO 67
Liparison
Lipidex
Lipidil
Lipidil Micro
Lipidil Supra
Lipidil ter
Lipidil-ter
Lipifen
Lipirex
Lipoclar
Lipofen
Lipofene
Liposit
Lipsin
Livesan
Lofibra
Luxacor
Merck dura brand OF procetofen
Micronized procetofen, antara
MTW Brand OF procetofen
MTW Fenofibrat
MTW-Fenofibrat
Nolipax
Normalip
Novartis brand OF procetofen
Novo fenofibrate
Novo-fenofibrate
Novopharm brand OF procetofen
NSC-281319
Nu fenofibrate
Nu pharm brand OF procetofen
Nu-fenofibrate
Nu-pharm brand OF procetofen
Pharmascience brand OF procetofen
Phenofibrate
PMS Fenofibrate micro
PMS-Fenofibrate micro
Procetofen
Procetofen reliant brand
Procetofen, antara micronized
Procetofene
Proctofene
Protolipan
Q Pharm brand OF procetofen
Q-Pharm brand OF procetofen
Ratiopharm brand OF procetofen
Reliant brand OF procetofen
Schering plough brand OF procetofen
Schering-plough brand OF procetofen
Secalip
Sedufen
Stada, fenofibrat
Stadapharm brand OF procetofen
Supralip
SUPRALIP 160
Tricor
TRICOR (TN)
Triglide
Trilipix
United drug brand OF procetofen
|
|
14 |
|
Isotretinoin |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
302-79-4, 4759-48-2 |
5538 444795 5282379 |
Synonyms:
(13-cis)-Retinoate
(13-CIS)-RETINOIC ACID
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXENYL)NONA-2,4,6,8-TETRAENOIC ACID
(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
(2Z,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAENOIC ACID
(7E,9E,11E,13Z)-Retinoate
(7E,9E,11E,13Z)-RETINOIC ACID
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
13 cis Retinoic acid
13 CIS-RETINOIC ACID
13-cis-Retinoate
13-cis-Retinoate,isotretinoin
13-CIS-RETINOIC ACID
13-CIS-VITAMIN A ACID
13-RA
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoate (ecl)
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
Aberel
ABSORICA
ACCUTANE
Acid, all-trans-retinoic
Acid, beta-all-trans-retinoic
Acid, retinoic
Acid, trans-retinoic
Acid, vitamin a
Acide retinoique
ACIDE RETINOIQUE (FRENCH)
ACIDE RETINOIQUE (FRENCH) (DSL)
ACTICIN
AGN 100335
Airol
Aknefug
Aknoten
all trans Retinoic acid
all trans-Retinoic acid
all-(e)-Retinoate
all-(e)-Retinoic acid
all-trans-beta-Retinoate
all-trans-beta-Retinoic acid
all-trans-b-Retinoate
all-trans-b-Retinoic acid
all-trans-Retinoate
all-trans-Retinoic acid
ALL-TRANS-RETINOIC ACID (ATRA)
all-trans-retinoic acid (ATRA)|Altreno® (0.05% lotion)|Avita® (0.025% gel)|Renova® (0.02% cream)
all-trans-Tretinoin
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-Β-retinoate
all-trans-Β-retinoic acid
ALTRENO
AMNESTEEM
ATRA
Atra-IV
Atralin
Avita
beta all trans Retinoic acid
beta-all-trans-Retinoic acid
beta-Retinoate
beta-Retinoic acid
b-Retinoate
b-Retinoic acid
CIP-isotretinoin
CIS-RA
cis-Retinoate
|
CIS-RETINOIC ACID
CLARAVIS
Dermairol
Eudyna
ISOTRETINOIN
Isotretinoin zinc salt, 13 cis isomer
Isotretinoin zinc salt, 13-cis-isomer
Isotretinoina
Isotretinoína
Isotretinoine
Isotrétinoine
Isotretinoino
Isotretinoinum
ISOTREX
Lsotretinoin
MYORISAN
NEOVITAMIN A ACID
NSC-122758
PAT-001
Potassium salt, tretinoin
Renova
Retin a
Retin-a
Retin-a micro
RETIN-A-MICRO
Retinoate
Retinoic acid
RETINOIC ACID 13-CIS-FORM
Retionic acid
Retisol-a
Ro 1-5488
RO-43780
RO-4-3780
Roaccutan
ROACCUTANE
Roacutan
Salt, tretinoin potassium
Salt, tretinoin sodium
Salt, tretinoin zinc
Sodium salt, tretinoin
Solage
SOTRET
Stieva-a
Stieva-a Forte
Teriosal
trans Retinoic acid
trans-Retinoate
trans-Retinoic acid
Tretin m
Tretinoin
Tretinoin potassium salt
Tretinoin sodium salt
Tretinoin zinc salt
TRETINOIN、ATRA
Tretinoina
Trétinoïne
TRETINOINE (FRENCH)
TRETINOINE (FRENCH) (EINECS)
Tretinoinum
Tretin-X
Tri-Luma
Vesanoid
Vitamin a acid
Vitinoin
ZENATANE
Zinc salt, tretinoin
Β-retinoate
Β-retinoic acid
|
|
15 |
|
Cenicriviroc |
Investigational |
Phase 2 |
|
497223-25-3 |
6320532 11285792 |
Synonyms:
(-)-8-(4-(2-Butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide
8-(4-(2-Butoxyethoxy)phenyl)-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-(4-((S)-((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1-benzazocine-5-carboxamide
CENICRIVIROC
Cénicriviroc
Cenicrivirocum
|
TAK 652
TAK 652|TAK-652|TAK652|TBR-652
TAK-652
TBR 652
TBR-652
|
|
16 |
|
Seladelpar |
Investigational |
Phase 2 |
|
851528-79-5 |
11476297 11236126 |
Synonyms:
2-[4-({2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl}sulfanyl)-2-methylphenoxy]acetate
2-[4-({2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl}sulphanyl)-2-methylphenoxy]acetate
2-[4-({2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl}sulphanyl)-2-methylphenoxy]acetic acid
|
compound 3r [PMID: 17524639]|MBX-8025|MBX8025
Seladelpar
|
|
17 |
|
Volixibat |
Experimental, Investigational |
Phase 2 |
|
1025216-57-2 |
|
Synonyms:
{[4-(benzyloxy)-6-[({3-[3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1-benzothiepin-5-yl]phenyl}-C-hydroxycarbonimidoyl)amino]-3,5-dihydroxyoxan-2-yl]methoxy}sulfonate
{[4-(benzyloxy)-6-[({3-[3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1-benzothiepin-5-yl]phenyl}-C-hydroxycarbonimidoyl)amino]-3,5-dihydroxyoxan-2-yl]methoxy}sulphonate
|
{[4-(benzyloxy)-6-[({3-[3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1-benzothiepin-5-yl]phenyl}-C-hydroxycarbonimidoyl)amino]-3,5-dihydroxyoxan-2-yl]methoxy}sulphonic acid
VOLIXIBAT
|
|
18 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
19 |
|
Hormones |
|
Phase 2 |
|
|
|
20 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
21 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
22 |
|
Antibodies |
|
Phase 2 |
|
|
|
23 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
24 |
|
Anti-Retroviral Agents |
|
Phase 2 |
|
|
|
25 |
|
Anti-HIV Agents |
|
Phase 2 |
|
|
|
26 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
27 |
|
2-chloro-3'-deoxyadenosine |
|
Phase 2 |
|
|
14485373 |
28 |
|
Interleukin-2 |
|
Phase 2 |
|
|
|
29 |
|
Analgesics |
|
Phase 2 |
|
|
|
30 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
31 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
32 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
33 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
34 |
|
Bile Acids and Salts |
|
Phase 2 |
|
|
|
35 |
|
Antimetabolites |
|
Phase 1, Phase 2 |
|
|
|
36 |
|
Hypolipidemic Agents |
|
Phase 1, Phase 2 |
|
|
|
37 |
|
Lipid Regulating Agents |
|
Phase 1, Phase 2 |
|
|
|
38 |
|
Keratolytic Agents |
|
Phase 2 |
|
|
|
39 |
|
Dermatologic Agents |
|
Phase 2 |
|
|
|
40 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
41 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
42 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
43 |
|
Calcium |
Nutraceutical |
Phase 2 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
44 |
|
Minocycline |
Approved, Investigational |
Phase 1 |
|
10118-90-8, 13614-98-7 |
54675783 5281021 |
Synonyms:
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
7-Dimethylamino-6-demethyl-6-deoxytetracycline
ACNAMINO
AKNEMIN
AKNEMIN 50
Alti-Minocycline
Apo-Minocycline
ARESTIN
BLEMIX 100
BLEMIX 50
CYCLOMIN
DENTOMYCIN
DYNACIN
Gen-Minocycline
KLINOMYCIN
MINO
Minociclina
Minociclina [INN-Spanish]
Minociclinum
MINOCIN
|
MINOCIN 50
MINOCIN MR
MINOCYCLIN
MINOCYCLINE
MINOCYCLINE HCL
MINOCYCLINE HYDROCHLORIDE
MINOCYCLINUM
Minocyclinum [INN-Latin]
Minocyn
MINOGAL
MINOLIRA
Minomycin
Novo-Minocycline
NSC-141993
SEBOMIN
SEBREN MR
SOLODYN
VECTRIN
XIMINO
|
|
45 |
|
Rifaximin |
Approved, Investigational |
Phase 1 |
|
80621-81-4 |
46783403 6436173 |
Synonyms:
(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,23,36-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6-oxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.1,.0,.0,.0,]heptatriaconta-1(35),2,4,9,19,21,23,25(36),26(34),28,30,32-dodecaen-13-yl acetic acid
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
NORMIX
Redactiv
RIFACOL
RIFAMYCIN L 105
RIFAMYCIN L 105SV
RIFAXIDIN
Rifaximin
|
RIFAXIMINA
RIFAXIMINE
RIFAXIMINUM
RIFAXIMINUN
TARGAXAN
Xifaxan
XIFAXANTA
XIFAXSAN
|
|
46 |
|
Erlotinib |
Approved, Investigational |
Phase 1 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
47 |
|
Budesonide |
Approved |
Phase 1 |
|
51333-22-3 |
5281004 40000 63006 |
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11Β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
AIRCORT
Bidien
BUDEFLAM AQUANASE
BUDELIN NOVOLIZER
BUDENOFALK
Budeson
Budesónida
BUDESONIDE
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budicort
CORTIMENT
Cortivent
Desowen
DEXBUDESONIDE
DUORESP SPIROMAX
ENTOCORT
ENTOCORT CR
Entocort ec
Entocort®|Eohilia® (budesonide oral suspension)|Jorveza®|Pulmicort®|S-1320|Uceris®
Horacort
MAP0010
|
MAP-0010
Micronyl
Noex
ORTIKOS
PREFERID
PULMAXAN
Pulmicort
PULMICORT FLEXHALER
PULMICORT L.S.
Pulmicort Nebuamp
PULMICORT RESPULES
Pulmicort Turbuhaler
R01AD05
Rhinocort
RHINOCORT ALLERGY
RHINOCORT AQUA
RHINOCORT AQUA 64
Rhinocort Turbuhaler
Rhinosol
S-1320
Spirocort
SYMBICORT
Tridesilon
Uceris
|
|
48 |
|
Metronidazole |
Approved |
Phase 1 |
|
443-48-1, 69198-10-3 |
4173 |
Synonyms:
1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(b-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(b-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(b-Oxyethyl)-2-methyl-5-nitroimidazole
1-(Β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(Β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(Β-oxyethyl)-2-methyl-5-nitroimidazole
2 Methyl 5 nitroimidazole 1 ethanol
2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-5-nitroimidazole-1-ethanol
ACEA
Acromona
ANABACT
Anagiardil
Apo-Metronidazole
Arilin
Atrivyl
BAY-5360
Bayer 5360
BAYER-5360
Bexon
Clont
Cont
Danizol
Deflamon
Deflamon-Wirkstoff
DRAZIFON
Efloran
ELYZOL
Entizol
Eumin
Flagemona
Flagesol
Flagil
Flagyl
FLAGYL 375
FLAGYL COMPAK
FLAGYL ER
Flagyl I.V.
FLAGYL I.V. RTU IN PLASTIC CONTAINER
FLAGYL-400
FLAGYL-S
Flegyl
Fossyol
Giatricol
Gineflavir
Hydrochloride, metronidazole
Klion
Klont
Meronidal
Methronidazole
Metric
METRIC 21
Metro Cream
Metro I.V.
Metro I.V. In Plastic Container
METRO IV
METROCREAM
Metrodzhil
MetroGel
Metrogel-vaginal
Metrogyl
Metrolag
METROLOTION
METROLYL
|
METROMIDOL
Metronidaz
Metronidazol
METRONIDAZOLE
Métronidazole
Metronidazole benzoate
Metronidazole Hcl
Metronidazole hydrochloride
Metronidazole in plastic container
Metronidazole monohydrochloride
Metronidazole phosphate
Metronidazole phosphoester
Metronidazolo
Metronidazolum
METROSA
METROTOP
Mexibol
Monagyl
Monasin
Monohydrochloride, metronidazole
Nalox
Neo-Tric
NEUTRATOP
Nida
Nidagel
Noritate
Noritic acid
NORZOL
Novonidazol
NSC-50364
NSC-69587
NUVESSA
Orvagil
Phosphate, metronidazole
Phosphoester, metronidazole
PROTOSTAT
Rathimed
ROSICED
ROZEX
RP-8823
Sanatrichom
Satric
Takimetol
Trichazol
Trichex
Tricho Cordes
Trichocide
Tricho-Gynaedron
Trichomol
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
Vagilen
Vagimid
VAGINYL
VANDAZOLE
Vertisal
Wagitran
ZADSTAT
ZIDOVAL
ZYOMET
|
|
49 |
|
Rituximab |
Approved |
Phase 1 |
|
174722-31-7 |
|
Synonyms:
ABP-798
ANTICD20
CT-P10
HS006
HS-006
HS-006 (RITUXIMAB BIOSIMILAR)
HSDB 7455|IDEC-C2B8|MabThera®|Rituxan®
IDEC-102
IDEC-C2B8
IG GAMMA-1 CHAIN C REGION
Ig gamma-2A chain C region, membrane-bound form
MABTHERA
MABTHERA RITUXAN
|
R-105 IDEC-102
radiolabeled murine anti-CD20
RG-105
RHCACD20MA
RITUXAN
RITUXIMAB
rituximab-abbs
rituximab-arrx
rituximab-pvvr
SAIT101
SAIT-101
Zevalin
|
|
50 |
|
Lenalidomide |
Approved |
Phase 1 |
|
191732-72-6 |
216326 |
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CC-5013
CC-5013|CDC-501|Revlimid®
CDC 501
CDC-501
Celgene brand OF lenalidomide
IMID-1
|
IMiD3
IMiD3 CPD
Lenalidomida
LENALIDOMIDE
Revimid
Revlimid
SYP-1512
|
|
Interventional clinical trials:
(show top 50)
(show all 114)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. |
Unknown status |
NCT02605213 |
Phase 4 |
Vancomycin;Placebo |
2 |
The Effect of Bezafibrate on Cholestatic Itch |
Unknown status |
NCT02701166 |
Phase 3 |
Bezafibrate;Placebo |
3 |
Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial |
Unknown status |
NCT00161148 |
Phase 3 |
Probiotics |
4 |
Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis |
Unknown status |
NCT01398917 |
Phase 3 |
|
5 |
Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects |
Completed |
NCT01802073 |
Phase 3 |
Oral Vancomycin |
6 |
Digital SpyGlass Cholangioscopy Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy |
Completed |
NCT02967926 |
Phase 3 |
|
7 |
Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing norUrsodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis |
Recruiting |
NCT03872921 |
Phase 3 |
norUrsodeoxycholic Acid |
8 |
Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy |
Recruiting |
NCT04309773 |
Phase 3 |
Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy;Placebo of Bezafibrate in addition to standard UDCA therapy |
9 |
A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing Cholangitis |
Recruiting |
NCT03710122 |
Phase 2, Phase 3 |
Vancomycin |
10 |
Effect of Simvastatin on the Prognosis of Primary Sclerosing Cholangitis (PSC); A Randomized, Double-blind, Placebo Controlled Multicenter Study |
Recruiting |
NCT04133792 |
Phase 3 |
Simvastatin 40mg;Placebo oral tablet |
11 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis |
Active, not recruiting |
NCT03890120 |
Phase 3 |
Cilofexor;Placebo |
12 |
Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis |
Terminated |
NCT00059202 |
Phase 2, Phase 3 |
Ursodeoxycholic Acid;Placebo |
13 |
A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease |
Withdrawn |
NCT03035058 |
Phase 3 |
Vedolizumab;Placebo |
14 |
Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis |
Unknown status |
NCT01688024 |
Phase 2 |
Mitomycin C;Normal saline |
15 |
A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis |
Completed |
NCT02061540 |
Phase 2 |
LUM001 |
16 |
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis |
Completed |
NCT02704364 |
Phase 2 |
|
17 |
Investigation of the Activity of Vidofludimus Calcium, a Novel, Orally Available, Small Molecule Inhibitor of Dihydroorotate Dehydrogenase, as a Treatment for Primary Sclerosing Cholangitis (PSC) |
Completed |
NCT03722576 |
Phase 2 |
Vidofludimus calcium |
18 |
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC) |
Completed |
NCT03333928 |
Phase 2 |
HTD1801;Placebo |
19 |
An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis |
Completed |
NCT02978339 |
Phase 1, Phase 2 |
Curcumin |
20 |
PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC) |
Completed |
NCT02653625 |
Phase 2 |
Cenicriviroc 150 mg |
21 |
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC) |
Completed |
NCT04024813 |
Phase 2 |
Seladelpar;Placebo to match Seladelpar |
22 |
A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC) |
Completed |
NCT01672853 |
Phase 2 |
|
23 |
Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. |
Completed |
NCT02424175 |
Phase 1, Phase 2 |
|
24 |
Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis |
Completed |
NCT00004762 |
Phase 2 |
cladribine |
25 |
A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC). |
Completed |
NCT02239211 |
Phase 2 |
BTT1023 |
26 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis |
Completed |
NCT02177136 |
Phase 2 |
Obeticholic Acid (OCA);Placebo |
27 |
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis |
Completed |
NCT02943460 |
Phase 2 |
Cilofexor;Placebo to match cilofexor |
28 |
Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis |
Completed |
NCT01755507 |
Phase 2 |
norUDCA;Placebo |
29 |
Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach |
Completed |
NCT01988506 |
Phase 2 |
Interleukin 2 |
30 |
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis |
Recruiting |
NCT04663308 |
Phase 2 |
Volixibat;Placebo |
31 |
A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC) |
Recruiting |
NCT04480840 |
Phase 2 |
PLN-74809;Placebo |
32 |
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating The Safety And Efficacy Of CM-101 In Subjects With Primary Sclerosing Cholangitis- The SPRING Study |
Recruiting |
NCT04595825 |
Phase 2 |
|
33 |
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis |
Recruiting |
NCT05525520 |
Phase 2 |
EP547;Placebo |
34 |
An Adaptive, Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis |
Recruiting |
NCT02997878 |
Phase 1, Phase 2 |
|
35 |
A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC) |
Recruiting |
NCT03561584 |
Phase 2 |
Sulfasalazine;Placebo |
36 |
Intra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis |
Active, not recruiting |
NCT03516006 |
Phase 1, Phase 2 |
UCMSC;UDCA |
37 |
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). |
Not yet recruiting |
NCT05627362 |
Phase 2 |
Elafibranor 80 mg;Elafibranor 120 mg;Placebo Matched to Elafibranor 80 mg;Placebo Matched to Elafibranor 120 mg |
38 |
An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults With Primary Sclerosing Cholangitis (PSC) |
Not yet recruiting |
NCT05642468 |
Phase 2 |
A3907 |
39 |
A Study of Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis(HAAPS Study). |
Not yet recruiting |
NCT05295680 |
Phase 2 |
Hymecromone |
40 |
An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis |
Terminated |
NCT03359174 |
Phase 2 |
All-trans retinoic acid |
41 |
A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) |
Terminated |
NCT03394781 |
Phase 2 |
DUR-928 |
42 |
Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis |
Terminated |
NCT00953615 |
Phase 2 |
Thalidomide |
43 |
Pilot Study of Fenofibrate in Primary Sclerosing Cholangitis |
Terminated |
NCT01142323 |
Phase 1, Phase 2 |
fenofibrate |
44 |
A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC) |
Withdrawn |
NCT03678480 |
Phase 2 |
HTD1801;Ursodeoxycholic Acid |
45 |
Primary Sclerosing Cholangitis: Value of Computerized Tomographic Cholangiography and Intraductal Volumetric Measurement in Determining the Prognosis |
Withdrawn |
NCT00588458 |
Phase 2 |
|
46 |
Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC) |
Completed |
NCT00630942 |
Phase 1 |
Minocycline |
47 |
A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis |
Completed |
NCT01695174 |
Phase 1 |
Xifaxan |
48 |
An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7 |
Completed |
NCT00955149 |
Phase 1 |
Erlotinib (Tarceva) |
49 |
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis |
Completed |
NCT00004842 |
Phase 1 |
budesonide |
50 |
A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis |
Completed |
NCT02464020 |
Phase 1 |
Vancomycin |
|